|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||
  Pediatric DiabetesVolume 9 Issue 3pt2, Pages 83 - 90 Published Online: 25 Jan 2008 © 2010 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 94K) | Related Articles | Citation Tracking  Original Article Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes Copyright Journal compilation © 2008 Blackwell Munksgaard KEYWORDS adolescents • children • HbA1c • insulin glargine • type 1 diabetes Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. ABSTRACTBackground: Insulin glargine is a long-acting insulin analogue increasingly used instead of neutral protamine Hagedorn (NPH) insulin in young subjects with type 1 diabetes. Objective: We evaluated the clinical course of diabetes in children and adolescents who were switched from NPH to insulin glargine. Methods: Between August 2003 and November 2004, a total of 76 subjects were switched to glargine in our clinic, treating 340 children with type 1 diabetes. All the subjects had been receiving insulin NPH, and their serum C-peptide levels had been non-detectable for at least 1 yr. Data were collected retrospectively, and 12–18 months after the change, experiences with glargine were inquired using a questionnaire. Seven subjects (9.2%) discontinued glargine before 12 months, and seven refused to participate. Results: Data for 62 subjects were analyzed. At the switch (0 months), their mean age was 12.7 yr (range 5.1–17.5), mean duration of diabetes was 6.7 yr (range 1.8–14.3), and mean hemoglobin A1c was (HbA1c) 9.2%. Twelve months later (+12 months), the mean HbA1c remained similar (9.2%), the proportion of long-acting insulin was smaller (47.7 vs. 58.1%; p < 0.001), and the daily insulin dose was lower (0.97 vs. 1.05 IU/kg; p < 0.001). The number of injections was lower at +12 months (17.7% with more than five injections vs. 64.5%; p < 0.001). No differences were seen in weight for height or the number of severe hypoglycemias. Most subjects who continued with glargine for ≥12 months considered glargine better than NPH. Conclusions: A switch to insulin glargine retains a similar glycemic control and does not change the number of severe hypoglycemias. Submitted 04 January 2007. Accepted for publication 05 September 2007 | 
|
